463 related articles for article (PubMed ID: 17118352)
1. Paraoxonase-1 concentrations in end-stage renal disease patients increase after hemodialysis: correlation with low molecular AGE adduct clearance.
Gugliucci A; Mehlhaff K; Kinugasa E; Ogata H; Hermo R; Schulze J; Kimura S
Clin Chim Acta; 2007 Feb; 377(1-2):213-20. PubMed ID: 17118352
[TBL] [Abstract][Full Text] [Related]
2. Acrolein inactivates paraoxonase 1: changes in free acrolein levels after hemodialysis correlate with increases in paraoxonase 1 activity in chronic renal failure patients.
Gugliucci A; Lunceford N; Kinugasa E; Ogata H; Schulze J; Kimura S
Clin Chim Acta; 2007 Sep; 384(1-2):105-12. PubMed ID: 17632094
[TBL] [Abstract][Full Text] [Related]
3. Low-molecular but not high-molecular advanced glycation end products (AGEs) are removed by high-flux dialysis.
Gerdemann A; Lemke HD; Nothdurft A; Heidland A; Münch G; Bahner U; Schinzel R
Clin Nephrol; 2000 Oct; 54(4):276-83. PubMed ID: 11076103
[TBL] [Abstract][Full Text] [Related]
4. Serum paraoxonase activity in uremic predialysis and hemodialysis patients.
Dirican M; Akca R; Sarandol E; Dilek K
J Nephrol; 2004; 17(6):813-8. PubMed ID: 15593056
[TBL] [Abstract][Full Text] [Related]
5. Oxidized low-density lipoprotein biomarkers in patients with end-stage renal failure: acute effects of hemodialysis.
Bossola M; Tazza L; Merki E; Giungi S; Luciani G; Miller ER; Lin EB; Tortorelli A; Tsimikas S
Blood Purif; 2007; 25(5-6):457-65. PubMed ID: 18075247
[TBL] [Abstract][Full Text] [Related]
6. Effect of hemodialysis on acid leukocyte-type ribonuclease, alkaline ribonuclease and polymorphonuclear elastase serum levels in patients with end-stage renal disease.
Naskalski JW; Kapusta M; Fedak D; Dumnicka P; Kuśnierz-Cabala B; Kuźniewski M; Sułowicz W
Nephron Clin Pract; 2009; 112(4):c248-54. PubMed ID: 19546584
[TBL] [Abstract][Full Text] [Related]
7. Profound mishandling of protein glycation degradation products in uremia and dialysis.
Agalou S; Ahmed N; Babaei-Jadidi R; Dawnay A; Thornalley PJ
J Am Soc Nephrol; 2005 May; 16(5):1471-85. PubMed ID: 15800128
[TBL] [Abstract][Full Text] [Related]
8. Impaired antioxidant activity of high-density lipoprotein in chronic kidney disease.
Moradi H; Pahl MV; Elahimehr R; Vaziri ND
Transl Res; 2009 Feb; 153(2):77-85. PubMed ID: 19138652
[TBL] [Abstract][Full Text] [Related]
9. Paraoxonase enzyme activity is enhanced by zinc supplementation in hemodialysis patients.
Rahimi-Ardabili B; Argani H; Ghorbanihaghjo A; Rashtchizadeh N; Naghavi-Behzad M; Ghorashi S; Nezami N
Ren Fail; 2012; 34(9):1123-8. PubMed ID: 22950600
[TBL] [Abstract][Full Text] [Related]
10. [Relation between paraoxonase activity, other HDL components and inflammatory state in hemodialyzed patients].
González AI; Brites F; Elbert A; Gómez-Rosso L; Berg G; Wikinski R; Schreier L
Medicina (B Aires); 2010; 70(6):508-12. PubMed ID: 21163737
[TBL] [Abstract][Full Text] [Related]
11. The meaning of serum levels of advanced glycosylation end products in diabetic nephropathy.
Shimoike T; Inoguchi T; Umeda F; Nawata H; Kawano K; Ochi H
Metabolism; 2000 Aug; 49(8):1030-5. PubMed ID: 10954022
[TBL] [Abstract][Full Text] [Related]
12. Enhanced plasma levels of advanced glycation end products (AGE) and pro-inflammatory cytokines in children/adolescents with chronic renal insufficiency and after renal replacement therapy by dialysis and transplantation--are they inter-related?
Sebeková K; Podracká L; Heidland A; Schinzel R
Clin Nephrol; 2001 Dec; 56(6):S21-6. PubMed ID: 11770807
[TBL] [Abstract][Full Text] [Related]
13. Effect of nandrolone decanonate on paraoxonase activity in hemodialysis patients.
Ghorbanihaghjo A; Argani H; Rahbaninoubar M; Rashtchizadeh N
Clin Biochem; 2005 Dec; 38(12):1076-80. PubMed ID: 16153628
[TBL] [Abstract][Full Text] [Related]
14. Serum paraoxonase levels in gastric cancer.
Akçay MN; Yilmaz I; Polat MF; Akçay G
Hepatogastroenterology; 2003 Dec; 50 Suppl 2():cclxxiii-cclxxv. PubMed ID: 15244199
[TBL] [Abstract][Full Text] [Related]
15. Soluble receptor for advanced glycation end products in patients with decreased renal function.
Kalousová M; Hodková M; Kazderová M; Fialová J; Tesar V; Dusilová-Sulková S; Zima T
Am J Kidney Dis; 2006 Mar; 47(3):406-11. PubMed ID: 16490618
[TBL] [Abstract][Full Text] [Related]
16. Serum paraoxonase levels in pancreatic cancer.
Akçay MN; Polat MF; Yilmaz I; Akçay G
Hepatogastroenterology; 2003 Dec; 50 Suppl 2():ccxxv-ccxxvii. PubMed ID: 15244186
[TBL] [Abstract][Full Text] [Related]
17. Clearance of increased serum advanced glycosylation end products in patients with end stage renal disease by hemodialysis.
Liu NF; Sun ZL; Liu BC
Acta Pharmacol Sin; 2000 Mar; 21(3):276-80. PubMed ID: 11324431
[TBL] [Abstract][Full Text] [Related]
18. Paraoxonase 1 arylesterase activity and mass are reduced and inversely related to C-reactive protein in patients on either standard or home nocturnal hemodialysis.
Kannampuzha J; Darling PB; Maguire GF; Donnelly S; McFarlane P; Chan CT; Connelly PW
Clin Nephrol; 2010 Feb; 73(2):131-8. PubMed ID: 20129020
[TBL] [Abstract][Full Text] [Related]
19. Oxidative stress and high-density lipoprotein function in Type I diabetes and end-stage renal disease.
Kalogerakis G; Baker AM; Christov S; Rowley KG; Dwyer K; Winterbourn C; Best JD; Jenkins AJ
Clin Sci (Lond); 2005 Jun; 108(6):497-506. PubMed ID: 15634192
[TBL] [Abstract][Full Text] [Related]
20. Advanced glycation end product free adducts are cleared by dialysis.
Agalou S; Ahmed N; Thornalley PJ; Dawnay A
Ann N Y Acad Sci; 2005 Jun; 1043():734-9. PubMed ID: 16037300
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
